3679-93-4

Basic information

• Product Name: Benzoic acid, 4-nitro-, 2-(aminoiminomethyl)hydrazide
• CAS NO: 3679-93-4
• Molecular Formula: C8H9N5O3
• Molecular Weight: 223.191
• Mol File: 3679-93-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-nitro-, 2-(aminoiminomethyl)hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-nitro-, 2-(aminoiminomethyl)hydrazide(3679-93-4)
• EPA Substance Registry System: Benzoic acid, 4-nitro-, 2-(aminoiminomethyl)hydrazide(3679-93-4)

Safety Data

• Hazardous Substances Data: 3679-93-4(Hazardous Substances Data)

Upstream product

• 2582-30-1 aminoguanidine bicarbonate 
• 122-04-3 4-nitro-benzoyl chloride 
• 14527-26-5 2-methylisothiourea sulphate 
• 636-97-5 N-amino-(4-nitrophenyl)carboxamide 

Downstream Products

• 20085-46-5 2-(4-nitrophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
• 1252014-25-7 C₁₂H₁₂N₆O₄S 
• 59301-21-2 3-(4-nitrophenyl)-1H-1,2,4-triazol-5-amine 
• 168893-40-1 5-(4-Amino-phenyl)-2H-[1,2,4]triazol-3-ylamine 

Relevant articles and documents

3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization

Many natural and synthetic substances are known to interfere with the dynamic assembly of tubulin, preventing the formation of microtubules. In our search for potent and selective antitumor agents, a novel series of 1-(3′,4′,5′-trimethoxybenzoyl)-5-amino-1,2,4-triazoles were synthesized. The compounds had different heterocycles, including thiophene, furan or the three isomeric pyridines, and they possessed a phenyl ring bearing electron-releasing or electron-withdrawing substituents at the 3-position of the 5-amino-1,2,4-triazole system. Most of the twenty-two tested compounds showed moderate to potent antiproliferative activities against a panel of solid tumor and leukemic cell lines, with four (5j, 5k, 5o and 5p) showing strong antiproliferative activity (IC50 50 values 2-100-fold lower for Jurkat and RS4;11 cells than those for the three lines derived from solid tumors (HeLa, HT-29 and MCF-7 cells). Compound 5k strongly inhibited tubulin assembly, with an IC50 value of 0.66 μM, half that obtained in simultaneous experiments with CA-4 (IC50 = 1.3 μM).

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.